{"organizations": [], "uuid": "bb4672f5cb4594478f5903ebe3d6dc90b82eb704", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-kalytera-initiates-program-to-deve/brief-kalytera-initiates-program-to-develop-a-novel-cannabinoid-based-compound-for-treatment-of-acute-and-chronic-pain-idUSFWN1R20DB", "country": "US", "domain_rank": 408, "title": "BRIEF-Kalytera Initiates Program To Develop A Novel Cannabinoid-Based Compound For Treatment Of Acute And Chronic Pain", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-20T14:11:00.000+02:00", "replies_count": 0, "uuid": "bb4672f5cb4594478f5903ebe3d6dc90b82eb704"}, "author": "", "url": "https://www.reuters.com/article/brief-kalytera-initiates-program-to-deve/brief-kalytera-initiates-program-to-develop-a-novel-cannabinoid-based-compound-for-treatment-of-acute-and-chronic-pain-idUSFWN1R20DB", "ord_in_thread": 0, "title": "BRIEF-Kalytera Initiates Program To Develop A Novel Cannabinoid-Based Compound For Treatment Of Acute And Chronic Pain", "locations": [], "entities": {"persons": [{"name": "kalytera", "sentiment": "none"}], "locations": [], "organizations": [{"name": "treatment of acute and chronic pain reuters staff", "sentiment": "none"}, {"name": "beetlebung pharma", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "kalytera therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 20, 2018 / 12:14 PM / Updated 22 minutes ago BRIEF-Kalytera Initiates Program To Develop A Novel Cannabinoid-Based Compound For Treatment Of Acute And Chronic Pain Reuters Staff 1 Min Read March 20 (Reuters) - Kalytera Therapeutics Inc: * KALYTERA INITIATES PROGRAM TO DEVELOP A NOVEL CANNABINOID-BASED COMPOUND FOR TREATMENT OF ACUTE AND CHRONIC PAIN * KALYTERA THERAPEUTICS INC - ‍KALYTERA OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FOR COMPOUND FROM BEETLEBUNG PHARMA, LTD​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-20T14:11:00.000+02:00", "crawled": "2018-03-20T14:46:13.032+02:00", "highlightTitle": ""}